One of the most potent CBD oil formulas on the market, SYNC 100 CBD, contains approximately 2000 mg of CBD per bottle. It is formulated with broad-spectrum whole-flower extract from cannabis grown in British Columbia and 100% organic coconut-derived, palm free oil for excellent quality and natural flavour.
| Potency: | CBD 94.5 – 115.5 mg/g THC 0.0-8.0 mg/g |
|---|---|
| Format | CBD Oil, 20 mL |
| Flavour | Natural: a smooth and earthy natural flavour of cannabis from whole flower cannabis extract and organic coconut oil. |
| Available in: | British Columbia, Alberta and Saskatchewan |
© Copyright 2020 | All Rights Reserved | Privacy Policy | Terms and Conditions | Whistleblower Policy
Mr. Bovenschen has over 16 years of progressive experience in financial management, project and operations management, strategy development and risk management. Before joining Emerald, he was a senior member of the construction joint venture responsible for the Riyadh metro project, a rapid transit system under construction in Saudi Arabia with a US$22B contract value. Mr. Bovenschen previously served in various management roles for Strukton, a leading construction and engineering firm in the Netherlands and earned a Master of Business Administration from Nyenrode Business University and a BBA from NCOI in Utrecht, Netherlands.
Ms. Wong has over 30 years of quality and regulatory management experience in pharmaceutical and life science companies regulated to Canadian, US, European and international requirements. She has been responsible for establishing quality systems and ensuring regulatory compliance through all phases of product development from GPP, GLP, GCP, GMP for cannabis, pharmaceuticals, medical devices, combination products and biologicals. She was previously Executive Director of Quality Assurance at Novelion Therapeutics (formerly QLT Inc.) and worked for life science companies including MDS Nordion, Cangene Corporation, and Biomira Inc. Ms. Wong earned a B.Sc. (Microbiology) from the University of Alberta.
Ms. Hepburn has over a decade of experience in accounting and finance and is an experienced manager of privately and publicly traded manufacturing and mining businesses operating in Canada and the USA. Prior to joining Emerald, Ms. Hepburn was the Director of Finance and Administration at bioLytical Laboratories Inc., a medical diagnostics manufacturer. Before that, she held controller positions at junior gold and silver mining companies Northern Vertex Mining Corp., Kootenay Silver Inc. and Theia Resources Ltd. Ms. Hepburn earned a BBA from Simon Fraser University and her certification from the Certified Management Accountants of British Columbia.
Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.
He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.
Mr. Bandali’s previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.
